Spinal analgesic action of endomorphins in acute, inflammatory and neuropathic pain in rats.

[1]  V. Hruby,et al.  Endomorphin-1 and endomorphin-2 are partial agonists at the human mu-opioid receptor. , 1998, European journal of pharmacology.

[2]  D. Selley,et al.  Endomorphin‐Stimulated [35S]GTPγS Binding in Rat Brain: Evidence for Partial Agonist Activity at μ‐Opioid Receptors , 1998 .

[3]  M. Wessendorf,et al.  Immunoreactivity for endomorphin‐2 occurs in primary afferents in rats and monkey , 1998, Neuroreport.

[4]  W. Sadee,et al.  Specific G protein activation and mu-opioid receptor internalization caused by morphine, DAMGO and endomorphin I. , 1998, European journal of pharmacology.

[5]  A. Kastin,et al.  Localization of Endomorphin-2-Like Immunoreactivity in the Rat Medulla and Spinal Cord , 1997, Peptides.

[6]  A. Kastin,et al.  Endomorphin 1 and 2, Endogenous Ligands for the μ-opioid Receptor, Decrease Cardiac Output, and Total Peripheral Resistance in the Rat , 1997, Peptides.

[7]  A. Kastin,et al.  Isolation of Relatively Large Amounts of Endomorphin-1 and Endomorphin-2 From Human Brain Cortex , 1997, Peptides.

[8]  A. Kastin,et al.  The endogenous mu-opioid agonists, endomorphin 1 and 2, have vasodilator activity in the hindquarters vascular bed of the rat. , 1997, Life sciences.

[9]  L. Stone,et al.  Spinal analgesic actions of the new endogenous opioid peptides endomorphin‐1 and ‐2 , 1997, Neuroreport.

[10]  A. Kastin,et al.  A potent and selective endogenous agonist for the µ-opiate receptor , 1997, Nature.

[11]  J. Hunter,et al.  The effect of novel anti-epileptic drugs in rat experimental models of acute and chronic pain. , 1997, European journal of pharmacology.

[12]  F. Porreca,et al.  Enhancement of the antiallodynic and antinociceptive efficacy of spinal morphine by antisera to dynorphin A (1–13) or MK-801 in a nerve-ligation model of peripheral neuropathy , 1997, Pain.

[13]  F. Porreca,et al.  Inhibition by spinal morphine of the tail-flick response is attenuated in rats with nerve ligation injury , 1995, Neuroscience Letters.

[14]  F. Porreca,et al.  The loss of antinociceptive efficacy of spinal morphine in rats with nerve ligation injury is prevented by reducing spinal afferent drive , 1995, Neuroscience Letters.

[15]  F. Porreca,et al.  Characterization of the antiallodynic efficacy of morphine in a model of neuropathic pain in rats. , 1995, Neuroreport.

[16]  K. Hole,et al.  The tail-flick and formalin tests in rodents: changes in skin temperature as a confounding factor , 1993, Pain.

[17]  W. Burkard,et al.  Synthesis and biological evaluation of 14-alkoxymorphinans. 2. (-)-N-(cyclopropylmethyl)-4,14-dimethoxymorphinan-6-one, a selective mu opioid receptor antagonist. , 1989, Journal of medicinal chemistry.

[18]  B. Meyerson,et al.  Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain , 1988, Pain.

[19]  W. Gispen,et al.  Methods for producing a reproducible crush in the sciatic and tibial nerve of the rat and rapid and precise testing of return of sensory function Beneficial effects of melanocortins , 1986, Journal of the Neurological Sciences.

[20]  R. Twycross,et al.  Morphine and Diamorphine in the Terminally Ill Patient , 1982, Acta anaesthesiologica Scandinavica. Supplementum.

[21]  T. Yaksh,et al.  Chronic catheterization of the spinal subarachnoid space , 1976, Physiology & Behavior.

[22]  T. Yaksh,et al.  Reversal of nerve ligation-induced allodynia by spinal alpha-2 adrenoceptor agonists. , 1995, The Journal of pharmacology and experimental therapeutics.